Considering that other factors such as variant-specific disease and CDH1 mutation penetrance likely also play a role in disease manifestation, early and precise determination of CDH1 mutation status remains an essential component of subsequent cancer detection in these patients, and screening protocols may become increasingly individualized as additional information regarding CDH1 P/LP mutations comes to light6–8,17. The gene discussed is CDH1; the disease is cancer.